JP2024525916A5 - - Google Patents
Info
- Publication number
- JP2024525916A5 JP2024525916A5 JP2024503724A JP2024503724A JP2024525916A5 JP 2024525916 A5 JP2024525916 A5 JP 2024525916A5 JP 2024503724 A JP2024503724 A JP 2024503724A JP 2024503724 A JP2024503724 A JP 2024503724A JP 2024525916 A5 JP2024525916 A5 JP 2024525916A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2021-0095142 | 2021-07-20 | ||
| KR20210095142 | 2021-07-20 | ||
| KR10-2021-0176638 | 2021-12-10 | ||
| KR20210176638 | 2021-12-10 | ||
| PCT/IB2022/056676 WO2023002390A1 (en) | 2021-07-20 | 2022-07-20 | Anti-cll-1 antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024525916A JP2024525916A (ja) | 2024-07-12 |
| JPWO2023002390A5 JPWO2023002390A5 (https=) | 2025-07-22 |
| JP2024525916A5 true JP2024525916A5 (https=) | 2025-07-22 |
Family
ID=84979134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024503724A Pending JP2024525916A (ja) | 2021-07-20 | 2022-07-20 | 抗ｃｌｌ－１抗体及びその用途 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250084158A1 (https=) |
| EP (1) | EP4373856A4 (https=) |
| JP (1) | JP2024525916A (https=) |
| KR (1) | KR20240035504A (https=) |
| WO (2) | WO2023002392A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4680647A2 (en) * | 2023-03-17 | 2026-01-21 | Memorial Sloan-Kettering Cancer Center | Antibodies targeting cd3 and uses thereof |
| CN117964760B (zh) * | 2023-12-21 | 2024-09-03 | 四川大学华西医院 | 抗人cll1/cd3的双特异性抗体及其应用 |
| GB202411940D0 (en) * | 2024-08-13 | 2024-09-25 | Univ Exeter | Anti-CLEC12A Antibodies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3470431A1 (en) * | 2012-09-27 | 2019-04-17 | Merus N.V. | Bispecific igg antibodies as t cell engagers |
| EP3310378B1 (en) * | 2015-06-16 | 2024-01-24 | F. Hoffmann-La Roche AG | Anti-cll-1 antibodies and methods of use |
| SI3115376T1 (sl) * | 2015-07-10 | 2018-12-31 | Merus N.V. | Humana protitelesa, ki vežejo CD3 |
| WO2019139888A1 (en) * | 2018-01-09 | 2019-07-18 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Compositions and methods for targeting clec12a-expressing cancers |
| CN111116753A (zh) * | 2018-10-30 | 2020-05-08 | 上海泰因生物技术有限公司 | 一种双特异性抗体的制备方法 |
| US11873338B2 (en) * | 2018-12-20 | 2024-01-16 | Merus N.V. | CLEC12AxCD3 bispecific antibodies and methods for the treatment of disease |
| JP7796008B2 (ja) * | 2019-09-13 | 2026-01-08 | メモリアル スローン ケタリング キャンサー センター | 抗ｃｄ３７１抗体およびその使用 |
-
2022
- 2022-07-20 WO PCT/IB2022/056679 patent/WO2023002392A1/en not_active Ceased
- 2022-07-20 EP EP22845538.2A patent/EP4373856A4/en active Pending
- 2022-07-20 US US18/580,552 patent/US20250084158A1/en active Pending
- 2022-07-20 WO PCT/IB2022/056676 patent/WO2023002390A1/en not_active Ceased
- 2022-07-20 KR KR1020247003739A patent/KR20240035504A/ko active Pending
- 2022-07-20 JP JP2024503724A patent/JP2024525916A/ja active Pending